Entrada Therapeutics, Inc. (TRDA) Tops Q4 EPS by 70c
Tweet
Share
E-mailGet Alerts TRDA Hot Sheet
Join SI Premium – FREE
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q4 EPS of $0.03, $0.70 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $37.4 million versus the consensus estimate of $13.34 million.
For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Wolfe Research sees CNH stock flat 2027 outlook on commodity prices
- Myriad Uranium completes acquisition of Rush Rare Metals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
